Milestone Pharmaceuticals (MIST) Capital Expenditures (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Capital Expenditures came in at $45000.0 in Q1 2026, up 650.0% YoY from $6000.0 in Q1 2025, and down 84.1% on a QoQ basis from $283000.0 in Q4 2025.
Milestone Pharmaceuticals (MIST) Capital Expenditures (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 7 years of Capital Expenditures data on file, last reported at $45000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 650.0% year-over-year to $45000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341000.0 (up 441.27% YoY) and the FY2025 annual result came in at $302000.0, up 815.15% from the prior year.
- Capital Expenditures declined to $45000.0 in Q1 2026, from $283000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $283000.0 in Q4 2025 to a low of $2000.0 in Q3 2025.
- A 5-year average of $53692.3 and a median of $31000.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 82.52% — and 2025, when it surged 1186.36%.
- Tracing MIST's Capital Expenditures over 5 years: stood at $110000.0 in 2022, then slumped by 71.82% to $31000.0 in 2023, then declined by 29.03% to $22000.0 in 2024, then surged by 1186.36% to $283000.0 in 2025, then plunged by 84.1% to $45000.0 in 2026.
- The last three Capital Expenditures figures came in at $45000.0 (Q1 2026), $283000.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Milestone Pharmaceuticals | 43.53 Mn | -127.97 Mn | - | 26,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26,000.00 |
| Jun 30, 2026 | 26,000.00 |
| Mar 31, 2026 | 45,000.00 |
| Mar 31, 2026 | 45,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Sep 30, 2023 | 18,000.00 |